Stephanie Lheureux
Princess Margaret Cancer Centre/University Health Network · Princess Margaret Cancer Centre, University Health Network · The Princess Margaret Cancer Foundation
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephanie Lheureux as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07840443 · Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaUniversity Health Network, Toronto · not yet recruiting · Estrogen Receptor-positive, Early Stage Endometrial Cancer · principal investigator
- Ph3NCT07286162 · Trauma-Focused Managing Cancer And Living Meaningfully (CALM-TF) for Newly Diagnosed and Recurrent Ovarian CancerUniversity Health Network, Toronto · not yet recruiting · Ovarian Cancer (OvCa), Recurrent Ovarian Cancer · principal investigator
- Ph1NCT06977126 · Study to Assess the Safety and Effects of Porphysome Nanoparticles for Imaging in Gynaecological CancersUniversity Health Network, Toronto · recruiting · Gynecological Cancers · principal investigator
- Ph1NCT06107868 · Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine CancerUniversity Health Network, Toronto · active not recruiting · Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer · principal investigator
- Ph2NCT05605509 · RP-6306 in Patients With Advanced CancerCanadian Cancer Trials Group · completed · Advanced Cancer · study chair
- Ph2NCT05065021 · Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorUniversity Health Network, Toronto · unknown · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer · principal investigator
- Ph2NCT04510584 · Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerUniversity Health Network, Toronto · withdrawn · Ovarian Endometrioid Tumor, Fallopian Tube Cancer, Primary Peritoneal Cancer · principal investigator
- N/ANCT04373005 · Screening of Cancer Patients to Assess Impact of COVID-19University Health Network, Toronto · terminated · Covid-19, Cancer · principal investigator
- N/ANCT04016389 · FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing SurgeryUniversity Health Network, Toronto · recruiting · Cervical Cancer · principal investigator
- Ph2NCT03587311 · Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · active not recruiting · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma · principal investigator
- Ph2NCT03480776 · ASA in Prevention of Ovarian Cancer (STICs and STONEs)Canadian Cancer Trials Group · active not recruiting · Ovarian Cancer Prevention · study chair
- Ph2NCT03367741 · Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerNational Cancer Institute (NCI) · active not recruiting · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma · principal investigator
- Ph1NCT03345784 · Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine CancersNational Cancer Institute (NCI) · terminated · Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm · principal investigator
- N/ANCT03260647 · Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological CancersUniversity Health Network, Toronto · completed · Gynecologic Cancer · principal investigator
- Ph1/Ph2NCT03081702 · A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian CancerUniversity Health Network, Toronto · completed · Platinum-resistant Epithelial Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- North American Star ConsortiumUM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2014 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:15 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Survival with Cemiplimab in Recurrent Cervical Cancer.N Engl J Med · 2022403 citationsRCR 28.6
- 182 citationsRCR 8.8
- Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.Clin Cancer Res · 2017129 citationsRCR 3.8
- 124 citationsRCR 9.7
- EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.Clin Cancer Res · 2020119 citationsRCR 4.8
- Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.Nat Med · 2023104 citationsRCR 7.4
- 90 citationsRCR 3.6
- A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia.Gynecol Oncol · 201562 citationsRCR 1.7
- 62 citationsRCR 3.3
- An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.J Immunother Cancer · 202060 citationsRCR 2.0